Clinical Trials Directory

Trials / Completed

CompletedNCT00871832

Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality

To Evaluate if Pre-admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit

Status
Completed
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
Northwell Health · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.

Conditions

Timeline

Start date
2007-05-01
Primary completion
2010-03-01
Completion
2010-03-01
First posted
2009-03-30
Last updated
2013-06-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00871832. Inclusion in this directory is not an endorsement.